| Literature DB >> 17521425 |
Godfred Futagbi1, Jennifer E Welbeck, John Kweku A Tetteh, Lars Hviid, Bartholomew D Akanmori.
Abstract
BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases. It is suspected that the polyclonal B-cell activation in P. falciparum malaria may precipitate a breakdown in homeostatic T-cell control of EBV-immortalized B-cell proliferation. Previous studies have suggested that a particular T-cell subset, characterized by expression of Vdelta1+ gammadelta T-cell receptors, is important for maintaining B-cell homeostasis, both in P. falciparum- exposed populations and in individuals subject to polyclonal B-cell activation of other aetiology. The objective of the present study was, therefore, to characterize lymphocyte phenotypes and to investigate possible differences in T-cell subset composition and activation status in P. falciparum-exposed Ghanaian children with and without eBL.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17521425 PMCID: PMC1894981 DOI: 10.1186/1475-2875-6-69
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Lymphocyte subset frequencies (median percentages [95% confidence intervals]*) in Burkitt's lymphoma patients and healthy control donors
| Subset | Healthy controls | eBL patients | Difference | P(T)* | |
| CD3+** | - | 81.7 [76.4 to 86.4] | 66.5 [47.6 to 72.1] | -15.4 [-34.1 to -7.5] | <0.001 |
| CD19+** | - | 0.4 [0.2 to 1.0] | 5.8 [4.8 to 8.8] | 5.4 [4.2 to 8.4] | <0.001 |
| CD3+ | CD4+ | 63.5 [53.6 to 65.7] | 68.0 [57.8 to 75.0] | 5.0 [-1.9 to 13.1] | 0.11 |
| CD3+ | CD8+ | 27.8 [26.6 to 31.7] | 20.9 [16.6 to 29.7] | -6.0 [-11. 5 to 1.8] | 0.08 |
| CD3+ | TCR- | 7.5 [4.9 to 15.5] | 3.3 [2.6 to 5.4] | -3.6 [-7.9 to -1.2] | 0.006 |
| TCR- | V | 45.2 [34.8 to 59.8] | 18.8 [14.2 to 29.8] | -25.2 [-35.4 to -15.1] | <0.001 |
| TCR- | V | 32.3 [12.3 to 45.1] | 9.2 [6.9 to 13.9] | -2 1.2 [-3 1.2 to -4.8] | 0.007 |
| TCR- | V | 7.7 [5.0 to 11. 7] | 9.8 [5.4 to 14.3] | 2.2 [-1.9 to 6.6] | 0.25 |
| TCR- | CD4+ | 4.8 [3.7 to 9.6] | 7.5 [4.9 to 34.8] | 2.9 [0.1 to 24.2] | 0.04 |
| TCR- | CD8+ | 31.2 [26.4 to 48.3] | 36.6 [26.0 to 45.9] | 0.0 [-8.0 to 11.0] | 0.98 |
* The statistical significance of differences in medians was calculated by the Mann-Whitney rank-sum test. Confidence intervals for median differences were calculated using CIA 2.0 software [1].
** Of all lymphocytes identified by forward and side scatter properties
Frequencies (median percentages [95% confidence intervals]*) of activated cells within lymphocyte subsets in Burkitt's lymphoma patients and healthy control donors
| Subset | Healthy controls | BL patients | Difference | P(T)* | |
| TCR- | CD25+ | 13.5 [9.3 to 16.9] | 8.0 [4.9 to 11.1] | -5.0 [-8.6 to -0.6] | 0.04 |
| TCR- | CD69+ | 4.1 [1.2 to 8.5] | 2.2 [1.1 to 4.6] | -1.2 [-4.2 to 0.8] | 0.20 |
| TCR- | HLA-DR + | 12.6 [7.6 to 21.1] | 20.2 [11. 4 to 30.0] | 7.2 [-0.6 to 16.9] | 0.07 |
| TCR- | CD95+ | 36.7 [29.1 to 44.8] | 45.4 [16.2 to 58.4] | 6.2 [-12.2 to 20.6] | 0.40 |
| TCR- | CD25+ | 1.6 [0.9 to 4.6] | 5.8 [2.6 to 11. 9] | 3.6 [1.0 to 8.1] | 0.007 |
| TCR- | CD69+ | 7.5 [2.0 to 14.6] | 8.9 [4.0 to 13.3] | 1.4 [-4.0 to 8.1] | 0.61 |
| TCR- | HLA-DR + | 33.3 [16.7 to 50.0] | 54.8 [39.6 to 67.8] | 22.7 [8.8 to 36.2] | 0.003 |
| TCR- | CD95+ | 42.5 [32.5 to 58.3] | 68.8 [30.4 to 89.0] | 21.3 [-1.7 to 41.0] | 0.10 |
* The statistical significance of differences in medians was calculated by the Mann-Whitney rank-sum test. Confidence intervals for median differences were calculated using CIA 2.0 software [1].
** Defined as CD3+ TCR-γδ-negative cells